Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer

BACKGROUND: The aim of this study was to improve activity over single human epidermal growth factor receptor 2 (HER2)-blockade sequential neaodjuvant regimens for HER2-positive breast cancer, by exploiting the concomitant administration of trastuzumab, taxane and anthracycline, while restraining car...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocca, Andrea, Cortesi, Pietro, Cortesi, Laura, Gianni, Lorenzo, Matteucci, Federica, Fantini, Lorenzo, Maestri, Antonio, Giunchi, Donata Casadei, Cavanna, Luigi, Ciani, Rosa, Falcini, Fabio, Bagni, Antonella, Meldoli, Elena, Dall’Agata, Monia, Volpi, Roberta, Andreis, Daniele, Nanni, Oriana, Curcio, Annalisa, Lucchi, Leonardo, Amadori, Dino, Fedeli, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876584/
https://www.ncbi.nlm.nih.gov/pubmed/33613693
http://dx.doi.org/10.1177/1758835920985632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876584/
https://www.ncbi.nlm.nih.gov/pubmed/33613693
http://dx.doi.org/10.1177/1758835920985632

Ejemplares similares